Anti-VEGFA ligand inhibitors. Bevacizumab is approved to treat CRC and RCC, and it is in phase II for prostate cancer. 140-5p is in pre-clinical testing to treat breast cancer. This evidence concerns the gene VEGFA and prostate carcinoma.